Drug Trial Radar · NCT07217015
A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis
Last checked: Nov 19, 2026Latest source record: Oct 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
200
Planned (sponsor's estimate)
Start
Nov 24, 2025
Primary completion
Jun 2027
Study completion Jun 2028
Sponsor
- Lead sponsor
- Kymera Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 15, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase 2b study is designed to evaluate the safety and efficacy of KT-621 in adult and adolescent participants with moderate-to-severe atopic dermatitis (AD), a common form of eczema. The main goals of this study are to learn how effective KT-621 is at reducing the severity and extent of AD, the safety and tolerability of KT-621, how KT-621 behaves in the body, and how the body responds to KT-621. This is a 16-week double-blind, placebo-controlled study with a 52-week open-label period.
Conditions
- Atopic Dermatitis
Interventions
KT-621Drug
Oral drug
PlaceboOther
Oral placebo matched to KT-621
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in Eczema Area and Severity Index (EASI) scoreTime frame: From baseline through Week 16
Locations
61 sites in 8 countries. Site status is shown where the registry gives one.
Kymera Investigative Site
Birmingham, Alabama
Kymera Investigative Site
North Little Rock, Arkansas
Kymera Investigative Site
Los Angeles, California
Kymera Investigative Site
Los Angeles, California
Kymera Investigative Site
Delray Beach, Florida
Kymera Investigative Site
Jacksonville, Florida
Kymera Investigative Site
Miami, Florida
Kymera Investigative Site
Miami, Florida
Kymera Investigative Site
Miramar, Florida
Kymera Investigative Site
Normal, Illinois
Kymera Investigative Site
Ann Arbor, Michigan
Kymera Investigative Site
Detroit, Michigan
Kymera Investigative Site
The Bronx, New York
Kymera Investigative Site
Fargo, North Dakota
Kymera Investigative Site
Portland, Oregon
Kymera Investigative Site
Portland, Oregon
Kymera Investigative Site
Philadelphia, Pennsylvania
Kymera Investigative Site
San Antonio, Texas
Kymera Investigative Site
San Antonio, Texas
Kymera Investigative Site
Darlinghurst, New South Wales, Australia
Kymera Investigative Site
Kogarah, New South Wales, Australia
Kymera Investigative Site
Brisbane, Queensland, Australia
Kymera Investigative Site
Woolloongabba, Queensland, Australia
Kymera Investigative Site
Melbourne, Victoria, Australia
Kymera Investigative Site
Calgary, Alberta, Canada
Kymera Investigative Site
Edmonton, Alberta, Canada
Kymera Investigative Site
Kelowna, British Columbia, Canada
Kymera Investigative Site
Surrey, British Columbia, Canada
Kymera Investigative Site
Markham, Ontario, Canada
Kymera Investigative Site
Ottawa, Ontario, Canada
Kymera Investigative Site
Richmond Hill, Ontario, Canada
Kymera Investigative Site
Toronto, Ontario, Canada
Kymera Investigative Site
Québec, Quebec, Canada
Kymera Investigative Site
Pardubice, Czechia
Kymera Investigative Site
Prague, Czechia
Kymera Investigative Site
Bad Bentheim, Germany
Kymera Investigative Site
Frankfurt, Germany
Kymera Investigative Site
Mainz, Germany
Kymera Investigative Site
Münster, Germany
Kymera Investigative Site
München, Bavaria, Germany
Showing 40 of 61 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.